Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
National Defense Authorization Act for Fiscal Year 2026
Client: VIATRIS INC · Firm: FEROX STRATEGIES
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
National Defense Authorization Act for Fiscal Year 2026
Client: VIATRIS INC · Firm: FEROX STRATEGIES
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VIATRIS INC via FEROX STRATEGIES
2026 · third_quarter · Q3
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2026 · third_quarter · Q3
Source: Senate LDA
| ATRIUM THERAPEUTICS |
| 4 |
| 2026 |
| SURGENEX | 4 | 2025–2026 |
| ALEXION PHARMACEUTICALS, INC. | 3 | 2026 |
| NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION (NEMA) | 3 | 2025–2026 |
| STOKE THERAPEUTICS | 3 | 2026 |
| AGE IN PLACE | 2 | 2026 |
| NEURELIS, INC. | 2 | 2026 |
| THE ERISA INDUSTRY COMMITTEE (ERIC) | 2 | 2026 |
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
National Defense Authorization Act for Fiscal Year 2026
Client: VIATRIS INC · Firm: FEROX STRATEGIES
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
National Defense Authorization Act for Fiscal Year 2026
Client: VIATRIS INC · Firm: FEROX STRATEGIES
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
General issues related to skin substitutes.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
STOKE THERAPEUTICS via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to rare disease treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to rare disease treatment development.
General issues related to rare disease treatment.
General issues related to tariffs.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
NEURELIS, INC. via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to epilepsy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION (NEMA) via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to radiopharmaceuticals.
General issues related to radiopharmaceutical tariffs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS KABI USA LLC via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to trade.
General healthcare issues related to biosimilar industries.
General patent issues related to biosimilar industries.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
THE ERISA INDUSTRY COMMITTEE (ERIC) via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to employer sponsored health plans.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via FEROX STRATEGIES
2026 · third_quarter · Q3
Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVIDITY BIOSCIENCES, INC. via FEROX STRATEGIES
2026 · third_quarter · 3T
Issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATRIUM THERAPEUTICS via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to the rare disease pharmaceutical ecosystem.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR ACCESSIBLE MEDICINES via FEROX STRATEGIES
2026 · third_quarter · Q3
General issues related to generic development and commercialization.
General issues related to trade.
General issues related to treatment access.
NEURELIS, INC. via FEROX STRATEGIES
2026 · third_quarter · RR
General issues related to federal regulation of the healthcare industry.
General issues related to federal regulation of the healthcare industry.
THE ERISA INDUSTRY COMMITTEE (ERIC) via FEROX STRATEGIES
2026 · third_quarter · RR
General issues related to employee sponsored health insurance.
General issues related to employee sponsored health insurance.
VIATRIS INC via FEROX STRATEGIES
2026 · second_quarter · Q2
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2026 · second_quarter · Q2
General issues related to skin substitutes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STOKE THERAPEUTICS via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to rare disease treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to tariffs.
General issues related to rare disease treatment.
General issues related to rare disease treatment development.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION (NEMA) via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to radiopharmaceutical tariffs.
General issues related to radiopharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS KABI USA LLC via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to trade.
General healthcare issues related to biosimilar industries.
General patent issues related to biosimilar industries.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via FEROX STRATEGIES
2026 · second_quarter · Q2
Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVIDITY BIOSCIENCES, INC. via FEROX STRATEGIES
2026 · second_quarter · Q2
Issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATRIUM THERAPEUTICS via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to the rare disease pharmaceutical ecosystem.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGE IN PLACE via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to digital health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ASSOCIATION FOR ACCESSIBLE MEDICINES via FEROX STRATEGIES
2026 · second_quarter · Q2
General issues related to generic development and commercialization.
General issues related to treatment access.
General issues related to patents and access to generics/biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS INC via FEROX STRATEGIES
2026 · first_quarter · Q1
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2026 · first_quarter · Q1
General issues related to skin substitutes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STOKE THERAPEUTICS via FEROX STRATEGIES
2026 · first_quarter · Q1
General issues related to rare disease treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via FEROX STRATEGIES
2026 · first_quarter · Q1
General issues related to tariffs.
General issues related to rare disease treatment.
General issues related to rare disease treatment development.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FRESENIUS KABI USA LLC via FEROX STRATEGIES
2026 · first_quarter · Q1
General healthcare issues related to biosimilar industries.
General patent issues related to biosimilar industries.
General issues related to trade.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via FEROX STRATEGIES
2026 · first_quarter · Q1
Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVIDITY BIOSCIENCES, INC. via FEROX STRATEGIES
2026 · first_quarter · Q1
Issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATRIUM THERAPEUTICS via FEROX STRATEGIES
2026 · first_quarter · Q1
General issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via FEROX STRATEGIES
2026 · first_quarter · Q1
Issues related to rare disease pharmaceuticals, ORPHAN Cures, and Pediatric Priority Review Voucher
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR ACCESSIBLE MEDICINES via FEROX STRATEGIES
2026 · first_quarter · Q1
General issues related to generic development and commercialization.
General issues related to treatment access.
General issues related to patents and access to generics/biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGE IN PLACE via FEROX STRATEGIES
2026 · first_quarter · RR
General issues related to digital health.
ASSOCIATION FOR ACCESSIBLE MEDICINES via FEROX STRATEGIES
2026 · first_quarter · RR
General issues related to generic and biosimilar drug development.
General issues related to generic and biosimilar drug development.
General issues related to generic and biosimilar drug development.
ATRIUM THERAPEUTICS via FEROX STRATEGIES
2026 · first_quarter · RR
General issues related to rare disease pharmaceuticals.
General issues related to rare disease pharmaceuticals.
VIATRIS INC via FEROX STRATEGIES
2025 · fourth_quarter · Q4
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2025 · fourth_quarter · Q4
General issues related to skin substitutes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via FEROX STRATEGIES
2025 · fourth_quarter · Q4
General issues related to rare disease treatment development.
General issues related to rare disease treatment.
General issues related to tariffs.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FRESENIUS KABI USA LLC via FEROX STRATEGIES
2025 · fourth_quarter · Q4
General healthcare issues related to biosimilar industries.
General patent issues related to biosimilar industries.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via FEROX STRATEGIES
2025 · fourth_quarter · Q4
Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVIDITY BIOSCIENCES, INC. via FEROX STRATEGIES
2025 · fourth_quarter · Q4
Issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via FEROX STRATEGIES
2025 · third_quarter · Q3
General issues related to rare disease treatment development.
General issues related to rare disease treatment.
General issues related to tariffs.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FRESENIUS KABI USA LLC via FEROX STRATEGIES
2025 · third_quarter · Q3
General healthcare issues related to generic and biosimilar industries.
General patent issues related to generic and biosimilar industries.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via FEROX STRATEGIES
2025 · third_quarter · Q3
Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVIDITY BIOSCIENCES, INC. via FEROX STRATEGIES
2025 · third_quarter · Q3
Issues related to rare disease pharmaceuticals, and general FDA reforms related to rare disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION (NEMA) via FEROX STRATEGIES
2025 · fourth_quarter · RR
General issues related to medical imaging and radio-pharmaceuticals.
General issues related to medical imaging and radio-pharmaceuticals.
VIATRIS INC via FEROX STRATEGIES
2025 · third_quarter · Q3
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
General issues related to patents and access to generics/biosimilars.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE